Feb 20, 2026Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis UpdateEvidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.
Feb 19, 2026Berberine for Metabolic Health: Evidence from Human TrialsBerberine activates AMPK through mild mitochondrial Complex I inhibition, producing improvements in glucose metabolism and modest weight loss in meta-analyses of clinical trials.
Feb 17, 2026Caloric Restriction Mimetics in 2025: Multi-Pathway Geroprotectors Under Clinical EvaluationA 2025 Biogerontology review maps geroprotective compounds targeting AMPK, mTOR, and autophagy pathways. Most remain at biomarker endpoints; hard longevity data in humans is largely absent.
Feb 6, 2026Berberine and AMPK: Metabolic Health, Blood Sugar, Lipids, and Comparison to MetforminBerberine activates AMPK through mechanisms similar to metformin and shows comparable glucose-lowering effects in head-to-head trials. Lipid-lowering effects are also well-supported. Bioavailability is limited but DHBerberine improves absorption.
Jan 23, 2026Blood Sugar and Glycation Management: Berberine, ALA, Chromium, and CarnosineElevated blood glucose accelerates aging through glycation (AGE formation), oxidative stress, and inflammation. Berberine and alpha-lipoic acid have strong glucose-lowering evidence. Carnosine and benfotiamine target the downstream glycation process. A comprehensive protocol addresses multiple pathways.
Jan 21, 2026Visceral Fat Reduction: Berberine, GLP-1 Context, Diet, and Exercise — Evidence ReviewVisceral adipose tissue is metabolically active and a major driver of chronic disease. Caloric deficit and exercise are primary — supplements like berberine and chromium provide meaningful but adjunctive support. GLP-1 context is relevant for clinical framing.